Compare · ELV vs SERA
ELV vs SERA
Side-by-side comparison of Elevance Health Inc. (ELV) and Sera Prognostics Inc. (SERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and SERA operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $86.50B, about 1005.8x SERA ($86.0M).
- Over the past year, ELV is up 28.7% and SERA is down 30.5% - ELV leads by 59.2 points.
- SERA has hit the wire 6 times in the past 4 weeks while ELV has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 8 for SERA).
- Company
- Elevance Health Inc.
- Sera Prognostics Inc.
- Price
- $398.89-0.87%
- $2.12+0.00%
- Market cap
- $86.50B
- $86.0M
- 1M return
- +5.43%
- +0.95%
- 1Y return
- +28.66%
- -30.49%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 6
- Recent ratings
- 23
- 8
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Sera Prognostics Inc.
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest ELV
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS
Latest SERA
- 1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
- Sera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
- SEC Form 10-Q filed by Sera Prognostics Inc.
- Sera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
- SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026
- Director Phillips Joshua was granted 24,686 shares, increasing direct ownership by 43% to 81,691 units (SEC Form 4)
- Director Mirza Mansoor Raza was granted 24,197 shares, increasing direct ownership by 42% to 81,937 units (SEC Form 4)
- Director Lawrence Sandra Aj was granted 24,702 shares, increasing direct ownership by 150% to 41,175 units (SEC Form 4)